Release on 2017-05-05 | by Tatjana Ábel,Gabriella Lengyel
Author: Tatjana Ábel,Gabriella Lengyel
Pubpsher: Bentham Science Publishers
Non-alcoholic fatty liver disease (NAFLD) is a common cause of elevated liver enzymes and chronic liver disease in Western countries. NAFLD is characterized by elevated liver enzymes in the absence of alcohol consumption and secondary causes of liver disease. It is an independent predictor of future risk of cardiovascular diseases, type 2 diabetes and metabolic syndrome (hypertension, abdominal obesity, dyslipidemia, glucose intolerance). This book is a quick reference guide for medical students and professionals about NAFLD. Readers will find a summary of epidemiology, clinical features, diagnosis, imaging techniques, histopathology, and disease management. The book also presents information about NAFLD linked with hepatocellular carcinoma and guidelines for treating NAFLD in pediatric patients. Each chapter presents information in a simple, structured manner making this text an ideal handbook for supplementing hepatology modules in medical curricula.
Release on 2013-02-06 | by Geoffrey C. Farrell,Arthur J. McCullough,Christopher P. Day
A Practical Guide
Author: Geoffrey C. Farrell,Arthur J. McCullough,Christopher P. Day
Pubpsher: John Wiley & Sons
The sharp rise in cases of Non-alcoholic fatty liver disease is fast becoming one of the major concerns for hepatologists worldwide. This comprehensive clinical guide explains how to diagnose NAFLD and manage patients according to the best standards of care. Contributors from the world's leading institutions concentrate on patient care, drawing on their extensive experience.
Non-alcoholic fatty liver disease (NAFLD) is the most common cause of chronic liver disease affecting approximately 25% of the global population and is commonly recognized as the hepatic manifestation of the metabolic syndrome. The histological spectrum of NAFLD ranges from isolated steatosis to non-alcoholic steatohepatitis (NASH), with risk of developing fibrosis and subsequent cirrhosis and hepatocellular carcinoma. The gold standard for diagnosing NAFLD is liver biopsy. However, because of its invasive nature, several non-invasive methods have been developed and validated in evaluating fat and fibrosis in patients with NAFLD. Liver fat content can be assessed using various methods. The conventional histopathological method consists of a visual semiquantitative approach in which the pathologist uses a four-point scale: grade 0 corresponds to fat deposition in <5% of hepatocytes and grade 1−3 (which is needed for the diagnosis of NAFLD) corresponds to ≥5%. An alternate approach is to quantitatively assess steatosis using stereological point counting (SPC) – which rely on liver biopsy. However, in vivo proton magnetic resonance spectroscopy (1H-MRS) is a reliable noninvasive method that can be used to quantitatively assess total hepatic lipid content, or proton density fat fraction (PDFF). In Paper I we compared the conventional semiquantitative histological method (grade 0-3) with SPC and 1H-MRS. We found a strong positive correlation between 1H-MRS and SPC, whereas the correlations between 1H-MRS or SPC and histopathological grading were substantially weaker. Using the widely used cut-off value of PDFF ≥5%, all participants were found to have steatosis (specificity 100%, sensitivity 53%). Reducing the cut-off value to 3% maintained 100% specificity while increasing sensitivity to 79%. In Paper IV we evaluated quantitative steatosis, by SPC, in 106 biopsy-proven NAFLD patients during a 20-year follow-up. SPC was independently associated with an increased risk of all-cause mortality and development of T2DM. Moreover, in the 59 patients with sequential biopsies (approximately 10 years apart), a reduction of quantitative hepatic steatosis decreased the all-time risk of developing T2DM. NASH is commonly seen as a histological feature portending a worse prognosis in NAFLD. Interestingly, no dual biopsy study has ever shown that NASH predicts fibrosis progression. Yet, NASH is seen as a surrogate marker in pharmaceutical trials – were resolution in NASH is equivalent to future resolution of fibrosis. In Paper II we conducted a long-term follow-up study (20 years) in a large cohort of biopsy-proven NAFLD patients (n=646), in a collaboration with Karolinska Institute. We could not ascertain that NASH had any effect on all-cause, or disease-specific mortality. However, higher stages of fibrosis predicted all-cause and disease specific mortality. In Paper III, we present 129 biopsy-proven NAFLD patients, in which we had prospective, longitudinal data. They were included between 1988 and 1993. All patients alive, were re-invited 2003-2005 and 2013-2015. Dual biopsies were present in 68 patients, and three consecutive biopsies were available in 33 patients. Results showed that NAFLD is a highly heterogeneous disease, with 9.3% developing end-stage liver disease and 16% progressing to advanced stages of fibrosis without any clinically significant baseline data predicting disease progression. In summary, when using 1H-MRS as a diagnostic method for NAFLD, the diagnostic cut-off should be reduced from 5% to 3%. Furthermore, quantitative amount of hepatic steatosis could be used to stratify patients with NAFLD related to future risk of developing T2DM. Moreover, we have shown that NASH does not predict future all-cause or disease-specific mortality nor end-stage liver disease, therefore a different surrogate marker should be used in clinical trials when assessing NAFLD improvement, so to not imbue false reliance in new therapies. Lastly, we have shown that NAFLD has a more dismal prognosis than previously reported, and that it is unexpectedly difficult to predict fibrosis progression in individual NAFLD patients, emphasizing the need for robust non-invasive biomarkers suitable to monitor large number of patients.
Alcoholic Fatty Liver: New Insights for the Healthcare Professional: 2011 Edition is a ScholarlyPaper™ that delivers timely, authoritative, and intensively focused information about Alcoholic Fatty Liver in a compact format. The editors have built Alcoholic Fatty Liver: New Insights for the Healthcare Professional: 2011 Edition on the vast information databases of ScholarlyNews.™ You can expect the information about Alcoholic Fatty Liver in this eBook to be deeper than what you can access anywhere else, as well as consistently reliable, authoritative, informed, and relevant. The content of Alcoholic Fatty Liver: New Insights for the Healthcare Professional: 2011 Edition has been produced by the world’s leading scientists, engineers, analysts, research institutions, and companies. All of the content is from peer-reviewed sources, and all of it is written, assembled, and edited by the editors at ScholarlyEditions™ and available exclusively from us. You now have a source you can cite with authority, confidence, and credibility. More information is available at http://www.ScholarlyEditions.com/.
Fatty liver disease is the most common type of liver disease seen in the world today. Some people with fatty liver disease simply have excess fat in the liver. Although not normal, it's not serious if it doesn't lead to inflammation or damage. However, once there's a build - up of fat, the liver becomes vulnerable to injury. Others have what's called non - alcoholic steatohepatisis (NASH). NASH can lead to permanent liver damage and cirrhosis. Both types of non - alcoholic fatty liver disease (NAFLD) are becoming more common. Up to 20% of adults have either fatty liver or NASH. The most common causes of fatty liver disease are obesity and diabetes mellitus. Written by experts and based on the most current information available, this indispensable guide is for anyone living with fatty liver disease. And diet plays a major role in managing the condition, so 100 specially selected recipes are also included.
This handbook examines the most common type of liver disease--fatty liver--and offers a comprehensive plan to reverse the condition and restore health. An extensive personal essay--"Confessions of a Fat Man" by Thomas Eanelli, MD--reveals a true-life example of one person's emotional battle with food addiction and fatty liver disease.
Fatty Liver: The Ultimate Guild To Treat, Cure And Reverse Fatty Liver Diseases.
Author: Dr Kelvin Joe
Fatty liver is also called hepatic statuses. It occurs whilst fats builds up in the liver. Having small amounts of fat to your liver is normal, however too much can grow to be a health hassle.Your liver is the second largest organ on your frame. It enables technique nutrients from foods and drinks and filters dangerous substances from your blood.Too an awful lot fat on your liver can cause liver inflammation, which may harm your liver and create scarring. In severe instances, this scarring can lead to liver failure.When fatty liver develops in someone who drinks a number of alcohols, it's referred to as alcoholic fatty liver sickness (AFLD).In a person who doesn't drink loads of alcohol, it's known as non-alcoholic fatty liver disease (NAFLD). According to researchers inside the World Journal of Gastroenterology, NAFLD impacts up to twenty-five to 30 percent of people within the United States and Europe. GET YOUR COPY NOW!
This volume covers a state-of-the-art illustration of recent discoveries concerning obesity-related fatty liver diseases and liver cancer. The contents are extensive and comprehensive. It brings important topics in the field all together under one umbrella, from epidemiology and etiology, molecular pathogenesis, cellular biology, epigenetics, immunology, microbiology, animal models to therapeutic approaches and treatments. All the book contributors are leading experts in the field. It will appeal to researchers, clinicians and graduate students in obesity, fatty liver diseases, GI/Liver cancer field. It may also yield benefits for pharmaceutical companies with regard to drug discovery.
Nonalcoholic fatty liver disease is one of the most common liver diseases worldwide affecting patients from all ages, races, and ethnic backgrounds. It comprises a spectrum of hepatic pathology ranging from simple steatosis, in which there is an increase of fat accumulation in hepatocytes, to nonalcoholic steatohepatitis and cirrhosis. The significant prevalence of this disease—between 15 and 45 percent of the general population—means that it contributes to an increased burden of ill health both today and in the future. Liver Metabolism and Fatty Liver Disease addresses the current understanding of the development of nonalcoholic fatty liver disease as well as the clinical aspects of the disease by examining the current knowledge surrounding metabolism in the liver. The book discusses various topics including the involvement of oxidative stress, metabolic effects, and inflammation as well as the effect of nutrition on the development and progression of the disease.
We would only stop talking about fatty liver disease, when the estimated 29 million people currently being affected in America alone begin to show remarkable improvements, and there's a sharp decrease in the number of people being affected. All over the world, this common liver problem, affecting both the young and the old, is at an alarming increase and must be addressed! You have fatty liver when there's excess fat in your liver. However, you can reverse it easily with the right information. If you delay, the fatty liver can deteriorate to more serious life-threatening conditions such as inflammation and scarring of the liver, of which, according to present statistics, up to 6.5 million people, will go on to experience. Don't join the number! This book is loaded with powerful information on how to address the fatty liver disease that affects millions of people all over the world today. Information is power; and with this book in your hands, you can reverse and prevent fatty liver disease and live a long and healthy life. So if you have been diagnosed with fatty liver, you now have the information necessary to reverse it naturally. And if you haven't, you are now equipped with how to prevent it for life! Since diet plays a crucial role in managing fatty liver, this book contains 85 specially selected natural recipes, low in saturated fats and high in fiber, that will enable you reverse and prevent fatty liver effortlessly. It will also aid weight loss. These recipes are categorized into Breakfast, Lunch, Dinner, Desserts, Snacks, Salads, Soups, Drinks and Smoothies. There are very easy to make with common ingredients that are readily available. These recipes are nutritiously delicious and will prove to you that being diagnosed with fatty liver does not mean that you can no longer enjoy good food. You need understanding about a change in your diet and lifestyle and this book presents you with this and many more. The Strategies In This Book Have Been Proven To Work. Get It Now And Take Can Take Control Of Your Life!